Eden Research plc AIM:EDEN
- Incorporated
- United Kingdom
- Chief executive
- Sean Smith
- Employees
- 23
- Reports in
- GBP
- Companies House
- 03071324
Read straight from the annual reports
2.4p at close on 5 Oct 2026 · 10 reported years, 2015–2024
| Line | FY201512/15 | FY201612/16 | FY201712/17 | FY201812/18 | FY201912/19 | FY202012/20 | FY202112/21 | FY202212/22 | FY202312/23 | FY202412/24 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Gross profit | |||||||||||
| Operating profit | |||||||||||
| Exceptional items | — | — | — | — | — | — | — | ||||
| Net finance cost | |||||||||||
| Profit before tax | |||||||||||
| Tax charge | |||||||||||
| Profit for the year | |||||||||||
| EBITDA | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Dividend per share | — | — | — | — | — | — | — | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
10 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Product sales of Mevalone and Cedroz
Product sales £3,577,020 (2023: £2,613,368), up 38%; 83% of 2024 revenue.
page 110R&D charges to partners
R&D charges £643,056 (2023: £510,457) in Agrochemicals £444,480 and Consumer products £198,576.
page 110Cost of sales up 70% vs revenue up 35%
Cost of sales £2,430,433 (2023: £1,426,547); gross profit £1,872,170 (2023: £1,765,480). Gross margin (computed from printed figures) fell from about 55% to about 44%.
page 76Elevated regulatory costs
Regulatory costs relatively high in 2024 due to renewal of Eden's three active ingredients in the EU; overheads expected to rise in 2025.
page 25Reiterated the £5 million revenue forecast for FY2025 (reiterated 13 January 2025), underpinned by repeat Ecovelex sales under extended emergency approval in Italy and other European territories, and sales growth of Mevalone and Cedroz from increased market share and 2024 approvals.
page 25Note 34: no adjusting or significant non-adjusting events between 31 December 2024 and approval of the financial statements.
page 149The Directors are unable to recommend any dividend for 2024. There is no near-term plan to pay a dividend; the Board continues to review dividend policy.
page 65Unmodified opinion; the auditor (PKF Littlejohn LLP) concluded no material uncertainty over going concern for at least 12 months from authorisation (2 May 2025). Management's base-case cash-flow forecast to 31 December 2026 keeps cash positive without new funding; the downside case (lower existing contract revenue, deferred R&D) also keeps cash positive. Note 1.3 states long-term positive cash generation depends on product development, registrations and new territories, and the Board may seek to invest more than currently affordable.
page 70- Regulatory approval timing and outcome gate the commercial pace (EU Ecovelex, Mevalone downy mildew, US and EU insecticide submissions).p.28
- Commercial failure to convert approvals into sales through partners; partnerships are the main route to market.p.28
- Customer concentration: three customers total 89.7% of revenue and Customer B alone 47.6%.p.112
- Trade receivable collection: £681,441 past due and average credit period 175 days.p.144
Read from C000407-AR-2024-ch.
9 annual reports read, FY2016 to FY2024
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (9)
FY2025Next report expected 11 May 2026